These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 24400675)
1. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Suzuki M; Hiramatsu M; Fukazawa M; Matsumoto M; Honda K; Suzuki Y; Kawabe Y Diabetes Obes Metab; 2014 Jul; 16(7):622-7. PubMed ID: 24400675 [TBL] [Abstract][Full Text] [Related]
2. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780 [TBL] [Abstract][Full Text] [Related]
3. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Davidson JA; Kuritzky L Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
5. Urinary tract infections in patients with diabetes treated with dapagliflozin. Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF J Diabetes Complications; 2013; 27(5):473-8. PubMed ID: 23849632 [TBL] [Abstract][Full Text] [Related]
6. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006 [TBL] [Abstract][Full Text] [Related]
7. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Cuypers J; Mathieu C; Benhalima K Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799 [TBL] [Abstract][Full Text] [Related]
8. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793 [TBL] [Abstract][Full Text] [Related]
9. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. Donnan JR; Grandy CA; Chibrikov E; Marra CA; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM BMJ Open; 2019 Feb; 9(1):e022577. PubMed ID: 30813108 [TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury. Chu C; Lu YP; Yin L; Hocher B Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics. Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977 [TBL] [Abstract][Full Text] [Related]
12. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641 [TBL] [Abstract][Full Text] [Related]
13. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371 [TBL] [Abstract][Full Text] [Related]
14. The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats. Gal A; Burton SE; Weidgraaf K; Singh P; Lopez-Villalobos N; Jacob A; Malabu U; Burchell R Domest Anim Endocrinol; 2020 Jan; 70():106376. PubMed ID: 31585313 [TBL] [Abstract][Full Text] [Related]
15. Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats. Chen L; LaRocque LM; Efe O; Wang J; Sands JM; Klein JD Am J Med Sci; 2016 Nov; 352(5):517-523. PubMed ID: 27865300 [TBL] [Abstract][Full Text] [Related]
16. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice. Dutta D; Kalra S J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168 [TBL] [Abstract][Full Text] [Related]
17. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830 [TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015 [TBL] [Abstract][Full Text] [Related]